FRI651 Usage Of Modern Sulphonylureas And Metformin Fixed Dose Combination (fdc) In Type 2 Diabetes Mellitus (t2dm) Patients With Established Complications

Disclosure: A. M: None. D. Prasad: None. D. Birla: None. L. Nagendra: None. B. Bansal: None. S. Shaikh: None. Aim: To evaluate the usage of sulphonylureas (SUs) and metformin fixed dose combinations (FDC) in type 2 diabetes mellitus (T2DM) patients with established complications Background: Patients with T2DM are at an increased risk of developing macrovascular and microvascular complications due to inadequate glycemic control. Therefore, it is crucial to understand various management strategies used for achieving intensive glycemic control in patients with T2DM having established complications Methodology: This was a retrospective multi-centric, cross-sectional study conducted at 670study sites. Patients of either sex, age above 18 years who have developed microvascular (neuropathy, nephropathy, retinopathy, foot ulcers, or any other complications) and/or macrovascular complications (CAD, stroke/transient ischemic attack, peripheral artery disease or heart failure) receiving any strength of glimepiride and metformin FDC for the treatment of T2DM were included. Data were analyzed using StatisticalPackage for The Social Sciences (SPSS) software, version 23.0. A paired samplet-test was used for comparing the pre-and post-treatment HbA1c, FPG and PPG levels. A P<0.05 was considered statistically significant. Results: A total of 470 patients with a mean age of 53.6 years were included. The majority of patients were obese (68.1%). Macrovascular complications were observed in 101 (21.5%) patients withT2DM, with CAD being the most common, affecting 69 (14.7%) patients. Microvascular complications were present in 408 (86.8%) patients with T2DM.Neuropathy and retinopathy were the leading microvascular complications, each affecting40.6% of patients with T2DM. A total of 73.8% of patients received glimepiride and metformin FDC as a first-line therapy. The strength of glimepiride 2 mg and metformin 500 mg (30.2%) was the most commonly prescribed combination. Presentation: Friday, June 16, 2023